Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the PCC CME article.

Overview

Certain antipsychotics are known to increase weight and the risk for diabetes. Could some medications for diabetes promote not only glycemic control but also weight loss in patients taking antipsychotics? In this CME activity, review the results of a small retrospective study.


Read the whole article at psychiatrist.com here: 
Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study

© Copyright 2020 Physicians Postgraduate Press, Inc.

Target Audience

Primary care clinicians

Learning Objectives

Monitor patients with severe mental illness who are taking antipsychotic medications for metabolic syndrome and diabetes so that treatment can be implemented as appropriate to minimize adverse cardiovascular outcomes

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
02/06/2020
Activity expires: 
02/28/2022
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Monitor patients with severe mental illness who are taking antipsychotic medications for metabolic syndrome and diabetes so that treatment can be implemented as appropriate to minimize adverse cardiovascular outcomes

Statement of Need and Purpose

Prescribers are advised to monitor patients for metabolic side effects of antipsychotics and appropriately treat obesity, dyslipidemia, and diabetes. Diabetes medications differentially impact weight and cardiovascular outcomes. Clinicians need education about studies of the efficacy of newer medications in diabetic patients who are taking antipsychotics, with or without antidepressants. Too few clinicians follow guidelines for monitoring metabolic risks in patients taking antipsychotics; education about newer interventions may encourage their increased assessment and treatment.

Release, Expiration, and Review Dates

This educational activity was published in February 2020 and is eligible for AMA PRA Category 1 Credit™ through February 28, 2022. The latest review of this material was January 2020.

Disclosure of off-label usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.

Funding/support

None.

Previous presentation

These data were presented as a published abstract at the Annual Meeting of the American Diabetes Association; June 22–26, 2018; Orlando, Florida.

Acknowledgments

The authors wish to thank Stephen R. Hammes, MD, PhD, and Steven D. Wittlin, MD, for their critical advice and review of the manuscript. Drs Hammes and Wittlin report no conflicts of interest related to the subject of this article.

Faculty Affiliation


Lauren T. Perlis, MD
Department of Family Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
 


J. Steven Lamberti, MD
Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York
 


Susanne U. Miedlich, MD*
Division of Endocrinology and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
 

*Corresponding author: Susanne U. Miedlich, MD, Division of Endocrinology and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 693, 601 Elmwood Ave, Rochester, NY 14642 (susanne_miedlich@urmc.rochester.edu).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Larry Culpepper, MD, MPH, Editor in Chief of The Primary Care Companion for CNS Disorders, has been a consultant for Acadia, Allergan, Eisai, Merck, Supernus, and Takeda; has been a stock shareholder of M-3 Information; and has received royalties from UpToDate and Oxford University Press. No member of the CME Institute staff reported any relevant personal financial relationships.

Drs PerlisLamberti, and Miedlich have no personal affiliations or financial relationships with any commercial interest to disclose relative to this article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

 

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.